Unlisted Deals:
×

S3v Vascular Technologies Annual Reports, Balance Sheet and Financials

Last Traded Price 390.00 + 0.00 %

S3v Vascular Technologies Limited (S3v Vascular) Return Comparision with Primex 40 Index

Periods 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years All Time
Primex-40
S3v Vascular Technologies Limited

S3v Vascular Technologies Limited Standalone Balance Sheet (Rs. in Thousands)

Particulars

31-03-2024

31-03-2023

Non-current Assets

 

 

Tangible assets

2,56,393.53

2,01,459.69

Intangible assets

1,157.97

1,453.80

Tangible assets capital WIP

18,572.58

14,080.66

Intangible assets under development or WIP

47,390.22

14,021.67

Long term loans and advances

1,12,834.43

1,23,541.60

Current Assets

 

 

Inventories

1,31,732.72

69,282.76

Trade receivables

3,70,831.72

3,39,701.41

Cash and bank balances

7,69,658.46

15,699.47

Other current assets

67,566.22

16,931.33

Total Assets

17,76,137.85

7,96,172.39

Non-current liabilities

 

 

Long term Borrowings

1,11,839.94

2,11,079.64

Deferred tax liabilities

18,980.65

17,587.98

Other Long term liabilities

14,981.93

35,737.57

Long term provisions

4,008.80

3,390.77

Current liabilities

 

 

Short term borrowings

1,41,199.83

85,960.72

Trade payables

43,581.07

40,746.44

Other current liabilities

32,700.27

10,369.40

Short term provisions

1,372.50

706.06

Equity

 

 

Share Capital

1,91,785.90

1,32,192.64

Reserves and surplus

12,15,686.96

2,58,401.17

Total Equity and Liabilities

17,76,137.85

7,96,172.39

S3v Vascular Technologies Limited Standalone Profit & Loss Statement (Rs. in Thousands)

Particulars

31-03-2024

31-03-2023

Income

 

 

Revenue from sale of products

1,49,274.81

1,88,988.44

Other income

2,274.43

809.58

Total Income

1,51,549.24

1,89,798.02

Expenses

 

 

Cost of material consumed

46,968.82

85,283.87

Change in inventories

7,849.42

-5,711.90

Employee benefit expenses

27,939.98

25,718.78

Finance costs

35,646.34

13,133.02

Depreciation expense

20,715.32

17,274.47

Other expenses

42,999.01

47,574.21

Total Expenses

1,82,118.89

1,83,272.45

Profit before tax

-30,569.65

6,525.57

Deferred Tax

1,392.68

908.84

Profit after tax

-31,962.33

5,616.73

Earnings per share

 

 

Basic

-2.37

0.43

Diluted

2.33

0.43

S3v Vascular Technologies Limited Standalone Cash Flow Statement (Rs. in Thousands)

Particulars

31-03-2024

31-03-2023

Cash Flow from Operating Activities

 

 

Profit before extraordinary items and tax

-30,569.65

6,525.57

Adjustments for:

 

 

Depreciation and amortization expenses

20,715.31

17,274.48

Inventories

-62,449.96

-12,798.41

Trade receivables

-81,765.19

-13,174.17

Trade payables

81,071.05

-14,076.13

Cash flow used in operations

-72,998.44

-16,248.66

Interest received

24,026.57

2,703.35

Income tax paid

-588.63

-212.81

Net Cash Flow from (used in) Operating Activities

-48,383.24

-13,332.50

Cash Flow from Investing activities

 

 

Purchase of tangible assets

1,15,717.30

37,033.50

Interest received

-588.64

-212.81

Other inflows/outflow of cash

13,210.67

-1,06,553.45

Net cash flow from (used in) Investing activities

-1,03,095.27

-1,43,799.97

Cash Flow from Financing Activities

 

 

Proceeds from issuing shares

10,48,841.38

36,374.45

Repayments of borrowings

99,239.71

-1,21,648.47

Interest paid

24,026.57

2,703.35

Other inflow/outflow of cash

-20,137.60

9,547.03

Net Cash flow from (used in) Financing activities

9,05,437.50

1,64,866.60

Net Increase/decrease in cash and cash equivalents

7,53,958.99

7,734.13

Cash and cash equivalents cash flow statement

at the end of the period

7,69,658.46

15,699.47

Summary of the Cash flow statement for the year 2024 and 2023:

Cash Flow from Operating Activities

During the year ended 31-03-2024, the company reported a loss before tax of ₹30,569.65 thousand, compared to a profit of ₹6,525.57 thousand in the previous year. Although non-cash expenses such as depreciation and amortization (₹20,715.31 thousand) were added back, operating cash flows were heavily impacted by a significant increase in working capital requirements. Inventories and trade receivables rose sharply, resulting in substantial cash outflows, while trade payables increased and partially offset this impact. Consequently, cash flow used in operations stood at ₹72,998.44 thousand. After accounting for interest received and income tax paid, the net cash flow from operating activities amounted to a negative ₹48,383.24 thousand, indicating that core operations consumed cash during the year. In comparison, the previous year also showed negative operating cash flows, but at a much lower level of ₹13,332.50 thousand.

Cash Flow from Investing Activities

The investing activities during FY 2023-24 resulted in a net cash outflow of ₹103,095.27 thousand. The major component was the purchase of tangible assets, reflecting continued investment in fixed assets. Additional cash movements arose from other investing inflows and outflows. Overall, this suggests that the company focused on capital expenditure and long-term investments. In the previous year, investing activities also resulted in a significant outflow of ₹143,799.97 thousand, indicating that the company has consistently been deploying cash into investment activities.

Cash Flow from Financing Activities

Financing activities were the primary source of cash inflow during FY 2023-24. The company raised substantial funds through the issuance of shares amounting to ₹1,048,841.38 thousand, which significantly strengthened liquidity. Additionally, there were cash inflows related to borrowings, though partly offset by repayments, interest payments, and other financing outflows. As a result, net cash flow from financing activities stood at ₹905,437.50 thousand, a sharp increase compared to ₹164,866.60 thousand in the previous year. This indicates strong reliance on external financing to support operations and investments.

Net Change in Cash and Cash Equivalents

Due to the large inflow from financing activities outweighing the cash outflows from operating and investing activities, the company recorded a net increase in cash and cash equivalents of ₹753,958.99 thousand during FY 2023-24. Consequently, cash and cash equivalents at the end of the period rose significantly to ₹769,658.46 thousand, compared to ₹15,699.47 thousand at the end of FY 2022-23.

S3v Vascular Technologies Annual Reports

S3v Vascular Technologies Annual Report 2023-24

Download
Support Puja Support Ishika Support Purvi

News Alert